

**RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE REQUESTED
EXAMINING GROUP 1649**

PATENT
Attorney Docket No. 08702.0093-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
WOLFMAN <i>et al.</i>)	Group Art Unit: 1649
)	
Application No.: 10/689,677)	Examiner: Aditi Dutt
)	
Filed: October 22, 2003)	Confirmation No.: 2405
)	
For: ACTRIIB Fusion Polypeptides and)	
Uses Therefor)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REPLY TO FINAL OFFICE ACTION

In reply to the Final Office Action mailed May 4, 2007, enclosed is a Petition for a One Month Extension and fee. Pursuant to 37 C.F.R. § 1.116, Applicants request amendment of this application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims beginning on page 4 of this paper.

Remarks/Arguments begin on page 9 of this paper.

Attachments to this amendment include:

- Declaration of Dr. Paul Yaworsky under 37 CFR § 1.132
- Ohsawa et al., J. Clin. Invest. 116:2924-2934 (2006)
- Alignment of amino acids 23-138 of SEQ ID NO:3 and amino acids 19-134 of SEQ ID NO:1
- Garg et al., Molecular and Cellular Endocrinology 153:169-181 (1999)